Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 1;32(6):515-520.
doi: 10.1097/ICU.0000000000000807.

Ophthalmic manifestations of dementing disorders

Affiliations
Review

Ophthalmic manifestations of dementing disorders

Vivian Paraskevi Douglas et al. Curr Opin Ophthalmol. .

Abstract

Purpose of review: Dementia is a term for loss of memory, language, problem-solving, and other thinking abilities, which significantly interferes with daily life. Certain dementing conditions may also affect visual function. The eye is an accessible window to the brain that can provide valuable information for the early diagnosis of people who suffer from Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies as well as from more rare causes of dementias, such as Creutzfeldt-Jacob and Huntington's diseases. Herein, we present the ocular manifestations of neurocognitive disorders focusing on the neuro-ophthalmic ones and further discuss potential ocular biomarkers that could help in early detection of these disorders.

Recent findings: Ophthalmic examination along with the recent developments in in-vivo testing have provided a strong foundation of useful knowledge about brain disorder in neurodegenerative diseases without the need for invasive studies. Currently, a number of visual measures, such as visual acuity, contrast sensitivity, pupil response, and saccades in addition to various ophthalmic tests, such as electroretinogram, visual evoked potential, optical coherence tomography (OCT), and OCT-angiography have been widely used and evaluated as potential biomarkers for different stages of dementia.

Summary: Ophthalmologic and neuro-ophthalmic evaluation is evolving as an important part of the early diagnosis and management of people with dementia. A particular focus on ocular biomarkers in dementing illnesses has arisen over the past few years and there are several promising measures and imaging tools that have been proposed as potential biomarkers for these diseases.

PubMed Disclaimer

References

    1. Gale SA, Acar D, Daffner KR. Dementia. Am J Med 2018; 131:1161–1169.
    1. International D. World Alzheimer Report 2019: attitudes to dementia; World Alzheimer Report 2019: attitudes to dementia [Internet]. 2019 Sep [Accessed 26 June 2021]. Available at: www.daviddesigns.co.uk .
    1. Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer disease. StatPearls [Internet] 2021; Treasure Island (FL): StatPearls Publishing, 1–27.
    1. Murphy MP, Levine H. Alzheimer's disease and the amyloid-β peptide. J Alzheimer's Dis 2010; 19:311–323.
    1. Singh A, Verma S. Use of ocular biomarkers as a potential tool for early diagnosis of Alzheimer's disease. Ind J Ophthalmol 2020; 68:555–561.